factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 920-924 | 920-924 | T60 | with | PROCESS_OF | 920 | 924 | preserve | 947-954 | 947-954 | T58 | disease | DiseaseOrSyndrome | 947 | 954 | preserve | 911-919 | 911-919 | T56 | patients | PatientOrDisabledGroup | 911 | 919 | A13 | However, there is continuous discussion concerning the utility of balloon angioplasty and renal stenting, respectively, in patients with atherosclerotic disease. | 782-955 | 782 | 955 | However, there is continuous discussion concerning the utility of balloon angioplasty and renal stenting, respectively, in @OBJECT$ @PREDICAT$ atherosclerotic @SUBJECT$ . |
Fact | preserve | 88-106 | 94-106 | T7 | stent implantation | USES | 88 | 106 | preserve | 94-106 | 94-106 | T6 | implantation | TherapeuticOrPreventiveProcedure | 94 | 106 | preserve | 88-93 | 88-93 | T5 | stent | MedicalDevice | 88 | 93 | A14 | stent implantation]. | 88-108 | 88 | 108 | @OBJECT$ @PREDICAT$ @SUBJECT$ ]. |
Fact | preserve | 653-659 | 653-659 | T51 | caused | CAUSES | 653 | 659 | preserve | 663-692 | 683-692 | T44 | fibromuscular dysplasia | DiseaseOrSyndrome | 663 | 692 | preserve | 649-652 | 649-652 | T43 | RAS | DiseaseOrSyndrome | 649 | 652 | A17 | Conventional balloon angioplasty of non-ostial RAS caused by fibromuscular dysplasia with a high technical and functional success rate may be the treatment of choice. | 602-781 | 602 | 781 | Conventional balloon angioplasty of non-ostial @OBJECT$ @PREDICAT$ by @SUBJECT$ with a high technical and functional success rate may be the treatment of choice. |
Possible | preserve | 495-504 | 495-504 | T35 | treatment | TREATS | 495 | 504 | preserve | 454-466 | 454-466 | T26 | implantation | TherapeuticOrPreventiveProcedure | 454 | 466 | preserve | 508-516 | 508-516 | T29 | patients | PatientOrDisabledGroup | 508 | 516 | A18 | In experienced hands renal artery revascularization with or without stent implantation may be a safe and effective treatment in patients with sustained hypertension resistant to intensive antihypertensive treatment. | 374-601 | 374 | 601 | In experienced hands renal artery revascularization with or without stent @SUBJECT$ may be a safe and effective @PREDICAT$ in @OBJECT$ with sustained hypertension resistant to intensive antihypertensive treatment. |
Fact | preserve | 1858-1862 | 1858-1862 | T116 | with | PROCESS_OF | 1,858 | 1,862 | preserve | 1863-1866 | 1863-1866 | T109 | RAS | DiseaseOrSyndrome | 1,863 | 1,866 | preserve | 1849-1857 | 1849-1857 | T108 | patients | PatientOrDisabledGroup | 1,849 | 1,857 | A19 | However, prior to any interventional treatment the indication of an eventual catheter procedure in patients with RAS should be discussed between experienced nephrologists and interventionalists based on clinical, functional and duplexsonographic data. | 1738-2007 | 1,738 | 2,007 | However, prior to any interventional treatment the indication of an eventual catheter procedure in @OBJECT$ @PREDICAT$ @SUBJECT$ should be discussed between experienced nephrologists and interventionalists based on clinical, functional and duplexsonographic data. |
Fact | preserve | 1464-1482 | 1470-1482 | T98 | stent implantation | USES | 1,464 | 1,482 | preserve | 1470-1482 | 1470-1482 | T88 | implantation | TherapeuticOrPreventiveProcedure | 1,470 | 1,482 | preserve | 1464-1469 | 1464-1469 | T87 | stent | MedicalDevice | 1,464 | 1,469 | A20 | In addition, the functional results suggest that stent implantation in patients with mild or severe renal dysfunction may slow progression of renal failure and, thus delay the need for renal replacement therapy. | 1409-1638 | 1,409 | 1,638 | In addition, the functional results suggest that @OBJECT$ @PREDICAT$ @SUBJECT$ in patients with mild or severe renal dysfunction may slow progression of renal failure and, thus delay the need for renal replacement therapy. |
Fact | preserve | 402-411 | 402-411 | T38 | treatment | TREATS | 402 | 411 | preserve | 428-435 | 428-435 | T31 | surgery | TherapeuticOrPreventiveProcedure | 428 | 435 | preserve | 479-503 | 491-503 | T33 | ventricular tachycardias | PathologicFunction | 479 | 503 | A1 | In the treatment of arrhythmias, surgery for supraventricular arrhythmias and ventricular tachycardias is discussed, as is the role of the automatic implantable cardioverter-defibrillator in the surgical treatment of ventricular tachycardias. | 395-655 | 395 | 655 | In the @PREDICAT$ of arrhythmias, @SUBJECT$ for supraventricular arrhythmias and @OBJECT$ is discussed, as is the role of the automatic implantable cardioverter-defibrillator in the surgical treatment of ventricular tachycardias. |
Fact | preserve | 726-739 | 732-739 | T48 | valve disease | LOCATION_OF | 726 | 739 | preserve | 726-731 | 726-731 | T42 | valve | BodyPartOrganOrOrganComponent | 726 | 731 | preserve | 732-739 | 732-739 | T43 | disease | DiseaseOrSyndrome | 732 | 739 | A2 | The usefulness of intraoperative echocardiography in evaluating valve disease, valve defects, and the results of surgical repair of atrioventricular septal defects is also discussed. | 656-850 | 656 | 850 | The usefulness of intraoperative echocardiography in evaluating @SUBJECT$ @PREDICAT$ @OBJECT$ , valve defects, and the results of surgical repair of atrioventricular septal defects is also discussed. |
Uncommitted | preserve | 8-11 | 8-11 | T9 | for | TREATS | 8 | 11 | preserve | 0-7 | 0-7 | T1 | Surgery | TherapeuticOrPreventiveProcedure | 0 | 7 | preserve | 25-46 | 36-46 | T3 | myocardial infarction | DiseaseOrSyndrome | 25 | 46 | A3 | Surgery for arrhythmias, myocardial infarction, pericardial disease, cardiac tumors, and trauma, and intraoperative echocardiography. | 0-139 | 0 | 139 | @SUBJECT$ @PREDICAT$ arrhythmias, @OBJECT$ , pericardial disease, cardiac tumors, and trauma, and intraoperative echocardiography. |
Fact | preserve | 402-411 | 402-411 | T38 | treatment | TREATS | 402 | 411 | preserve | 428-435 | 428-435 | T31 | surgery | TherapeuticOrPreventiveProcedure | 428 | 435 | preserve | 440-468 | 457-468 | T32 | supraventricular arrhythmias | PathologicFunction | 440 | 468 | A4 | In the treatment of arrhythmias, surgery for supraventricular arrhythmias and ventricular tachycardias is discussed, as is the role of the automatic implantable cardioverter-defibrillator in the surgical treatment of ventricular tachycardias. | 395-655 | 395 | 655 | In the @PREDICAT$ of arrhythmias, @SUBJECT$ for @OBJECT$ and ventricular tachycardias is discussed, as is the role of the automatic implantable cardioverter-defibrillator in the surgical treatment of ventricular tachycardias. |
Fact | preserve | 276-279 | 276-279 | T28 | for | TREATS | 276 | 279 | preserve | 268-275 | 268-275 | T21 | surgery | TherapeuticOrPreventiveProcedure | 268 | 275 | preserve | 280-291 | 280-291 | T22 | arrhythmias | PathologicFunction | 280 | 291 | A5 | This brief review highlights some of the advances made in selected areas of cardiac surgery over the past year, including surgery for arrhythmias, complications of myocardial infarction, pericardial disease, cardiac tumors, and trauma. | 140-394 | 140 | 394 | This brief review highlights some of the advances made in selected areas of cardiac surgery over the past year, including @SUBJECT$ @PREDICAT$ @OBJECT$ , complications of myocardial infarction, pericardial disease, cardiac tumors, and trauma. |
Uncommitted | preserve | 8-11 | 8-11 | T9 | for | TREATS | 8 | 11 | preserve | 0-7 | 0-7 | T1 | Surgery | TherapeuticOrPreventiveProcedure | 0 | 7 | preserve | 69-89 | 83-89 | T5 | cardiac tumors | NeoplasticProcess | 69 | 89 | A6 | Surgery for arrhythmias, myocardial infarction, pericardial disease, cardiac tumors, and trauma, and intraoperative echocardiography. | 0-139 | 0 | 139 | @SUBJECT$ @PREDICAT$ arrhythmias, myocardial infarction, pericardial disease, @OBJECT$ , and trauma, and intraoperative echocardiography. |
Uncommitted | preserve | 8-11 | 8-11 | T9 | for | TREATS | 8 | 11 | preserve | 0-7 | 0-7 | T1 | Surgery | TherapeuticOrPreventiveProcedure | 0 | 7 | preserve | 12-23 | 12-23 | T2 | arrhythmias | PathologicFunction | 12 | 23 | A7 | Surgery for arrhythmias, myocardial infarction, pericardial disease, cardiac tumors, and trauma, and intraoperative echocardiography. | 0-139 | 0 | 139 | @SUBJECT$ @PREDICAT$ @OBJECT$ , myocardial infarction, pericardial disease, cardiac tumors, and trauma, and intraoperative echocardiography. |
Uncommitted | preserve | 8-11 | 8-11 | T9 | for | TREATS | 8 | 11 | preserve | 0-7 | 0-7 | T1 | Surgery | TherapeuticOrPreventiveProcedure | 0 | 7 | preserve | 48-67 | 60-67 | T4 | pericardial disease | DiseaseOrSyndrome | 48 | 67 | A8 | Surgery for arrhythmias, myocardial infarction, pericardial disease, cardiac tumors, and trauma, and intraoperative echocardiography. | 0-139 | 0 | 139 | @SUBJECT$ @PREDICAT$ arrhythmias, myocardial infarction, @OBJECT$ , cardiac tumors, and trauma, and intraoperative echocardiography. |
Uncommitted | preserve | 8-11 | 8-11 | T9 | for | TREATS | 8 | 11 | preserve | 0-7 | 0-7 | T1 | Surgery | TherapeuticOrPreventiveProcedure | 0 | 7 | preserve | 95-101 | 95-101 | T6 | trauma | InjuryOrPoisoning | 95 | 101 | A10 | Surgery for arrhythmias, myocardial infarction, pericardial disease, cardiac tumors, and trauma, and intraoperative echocardiography. | 0-139 | 0 | 139 | @SUBJECT$ @PREDICAT$ arrhythmias, myocardial infarction, pericardial disease, cardiac tumors, and @OBJECT$ , and intraoperative echocardiography. |
Fact | preserve | 537-555 | 547-555 | T53 | Alzheimer patients | PROCESS_OF | 537 | 555 | preserve | 537-546 | 537-546 | T37 | Alzheimer | DiseaseOrSyndrome | 537 | 546 | preserve | 547-555 | 547-555 | T38 | patients | PatientOrDisabledGroup | 547 | 555 | A2 | Two groups of Alzheimer patients were studied: a group with moderate Alzheimer's disease (n = 6, 9<MMS<20) and a severe Alzheimer group (n = 13, MMS<9) who were compared with an age-matched control group (n = 10, MMS>23) and a group of subjects with diabetes (n = 31). | 523-809 | 523 | 809 | Two groups of @SUBJECT$ @PREDICAT$ @OBJECT$ were studied: a group with moderate Alzheimer's disease (n = 6, 9<MMS<20) and a severe Alzheimer group (n = 13, MMS<9) who were compared with an age-matched control group (n = 10, MMS>23) and a group of subjects with diabetes (n = 31). |
Fact | preserve | 255-269 | 263-269 | T20 | sugars (hexose | ISA | 255 | 269 | preserve | 271-278 | 271-278 | T15 | pentose | Carbohydrate | 271 | 278 | preserve | 255-261 | 255-261 | T13 | sugars | Carbohydrate | 255 | 261 | A4 | These AGEs can be produced by various sugars (hexose, pentose, glyceraldehyde and oxidative products of vitamin C). | 211-338 | 211 | 338 | These AGEs can be produced by various @OBJECT$ @PREDICAT$ , @SUBJECT$ , glyceraldehyde and oxidative products of vitamin C). |
Fact | preserve | 993-1008 | 1000-1008 | T80 | Plasma furosine | LOCATION_OF | 993 | 1,008 | preserve | 993-999 | 993-999 | T67 | Plasma | BodySubstance | 993 | 999 | preserve | 1000-1008 | 1000-1008 | T68 | furosine | AminoAcidPeptideOrProtein | 1,000 | 1,008 | A5 | Protein glycation was evaluated in plasma with a highly specific HPLC-UV technique, using furosine, which is the acid hydrolysis product of epsilon-deoxy-fructosyl-lysine Plasma furosine was almost two times higher in subjects with Alzheimer's disease (p<.005) than in controls, but still 50% lower than in diabetic patients (P<.02). | 810-1168 | 810 | 1,168 | Protein glycation was evaluated in plasma with a highly specific HPLC-UV technique, using furosine, which is the acid hydrolysis product of epsilon-deoxy-fructosyl-lysine @SUBJECT$ @PREDICAT$ @OBJECT$ was almost two times higher in subjects with Alzheimer's disease (p<.005) than in controls, but still 50% lower than in diabetic patients (P<.02). |
Fact | preserve | 445-449 | 445-449 | T33 | with | PROCESS_OF | 445 | 449 | preserve | 450-469 | 462-469 | T28 | Alzheimer's disease | DiseaseOrSyndrome | 450 | 469 | preserve | 436-444 | 436-444 | T27 | patients | PatientOrDisabledGroup | 436 | 444 | A7 | In this study, we quantified plasma protein glycation specifically derived from glucose in patients with Alzheimer's disease with different grades of cognitive disorders. | 339-522 | 339 | 522 | In this study, we quantified plasma protein glycation specifically derived from glucose in @OBJECT$ @PREDICAT$ @SUBJECT$ with different grades of cognitive disorders. |
Fact | preserve | 255-269 | 263-269 | T20 | sugars (hexose | ISA | 255 | 269 | preserve | 263-269 | 263-269 | T14 | hexose | Carbohydrate | 263 | 269 | preserve | 255-261 | 255-261 | T13 | sugars | Carbohydrate | 255 | 261 | A8 | These AGEs can be produced by various sugars (hexose, pentose, glyceraldehyde and oxidative products of vitamin C). | 211-338 | 211 | 338 | These AGEs can be produced by various @OBJECT$ @PREDICAT$ @SUBJECT$ , pentose, glyceraldehyde and oxidative products of vitamin C). |
Fact | preserve | 1142-1159 | 1151-1159 | T81 | diabetic patients | PROCESS_OF | 1,142 | 1,159 | preserve | 1142-1150 | 1142-1150 | T77 | diabetic | Finding | 1,142 | 1,150 | preserve | 1151-1159 | 1151-1159 | T78 | patients | PatientOrDisabledGroup | 1,151 | 1,159 | A9 | Protein glycation was evaluated in plasma with a highly specific HPLC-UV technique, using furosine, which is the acid hydrolysis product of epsilon-deoxy-fructosyl-lysine Plasma furosine was almost two times higher in subjects with Alzheimer's disease (p<.005) than in controls, but still 50% lower than in diabetic patients (P<.02). | 810-1168 | 810 | 1,168 | Protein glycation was evaluated in plasma with a highly specific HPLC-UV technique, using furosine, which is the acid hydrolysis product of epsilon-deoxy-fructosyl-lysine Plasma furosine was almost two times higher in subjects with Alzheimer's disease (p<.005) than in controls, but still 50% lower than in @SUBJECT$ @PREDICAT$ @OBJECT$ (P<.02). |
Fact | preserve | 84-93 | 84-93 | T11 | formation | LOCATION_OF | 84 | 93 | preserve | 150-155 | 150-155 | T8 | brain | BodyPartOrganOrOrganComponent | 150 | 155 | preserve | 97-128 | 116-128 | T7 | advanced glycation end-products | BiologicallyActiveSubstance | 97 | 128 | A11 | Recent studies have suggested that formation of advanced glycation end-products (AGEs) in some brain proteins could be associated with Alzheimer's disease. | 49-210 | 49 | 210 | Recent studies have suggested that @PREDICAT$ of @OBJECT$ (AGEs) in some @SUBJECT$ proteins could be associated with Alzheimer's disease. |
Fact | preserve | 255-269 | 263-269 | T20 | sugars (hexose | ISA | 255 | 269 | preserve | 280-294 | 280-294 | T16 | glyceraldehyde | Carbohydrate | 280 | 294 | preserve | 255-261 | 255-261 | T13 | sugars | Carbohydrate | 255 | 261 | A12 | These AGEs can be produced by various sugars (hexose, pentose, glyceraldehyde and oxidative products of vitamin C). | 211-338 | 211 | 338 | These AGEs can be produced by various @OBJECT$ @PREDICAT$ , pentose, @SUBJECT$ and oxidative products of vitamin C). |
Fact | preserve | 1858-1860 | 1858-1860 | T127 | in | TREATS | 1,858 | 1,860 | preserve | 1849-1857 | 1849-1857 | T116 | warfarin | HazardousOrPoisonousSubstance | 1,849 | 1,857 | preserve | 1874-1882 | 1874-1882 | T119 | patients | PatientOrDisabledGroup | 1,874 | 1,882 | A1 | The underutilization of aspirin and warfarin in older stroke patients with dementia may be a modifiable basis for their increased risk of recurrence and death. | 1807-1978 | 1,807 | 1,978 | The underutilization of aspirin and @SUBJECT$ @PREDICAT$ older stroke @OBJECT$ with dementia may be a modifiable basis for their increased risk of recurrence and death. |
Fact | preserve | 1711-1715 | 1711-1715 | T113 | with | USES | 1,711 | 1,715 | preserve | 1698-1710 | 1698-1710 | T107 | nontreatment | HealthCareActivity | 1,698 | 1,710 | preserve | 1733-1741 | 1733-1741 | T109 | warfarin | HazardousOrPoisonousSubstance | 1,733 | 1,741 | A2 | CONCLUSIONS: Our results suggest that dementia is a significant independent determinant of nontreatment with aspirin or warfarin when otherwise indicated for the prevention of recurrent stroke. | 1601-1806 | 1,601 | 1,806 | CONCLUSIONS: Our results suggest that dementia is a significant independent determinant of @SUBJECT$ @PREDICAT$ aspirin or @OBJECT$ when otherwise indicated for the prevention of recurrent stroke. |
Fact | preserve | 1858-1860 | 1858-1860 | T127 | in | TREATS | 1,858 | 1,860 | preserve | 1837-1844 | 1837-1844 | T115 | aspirin | OrganicChemical | 1,837 | 1,844 | preserve | 1888-1896 | 1888-1896 | T120 | dementia | MentalOrBehavioralDysfunction | 1,888 | 1,896 | A3 | The underutilization of aspirin and warfarin in older stroke patients with dementia may be a modifiable basis for their increased risk of recurrence and death. | 1807-1978 | 1,807 | 1,978 | The underutilization of @SUBJECT$ and warfarin @PREDICAT$ older stroke patients with @OBJECT$ may be a modifiable basis for their increased risk of recurrence and death. |
Uncommitted | preserve | 738-745 | 738-745 | T57 | effects | AFFECTS | 738 | 745 | preserve | 845-852 | 845-852 | T53 | aspirin | OrganicChemical | 845 | 852 | preserve | 773-781 | 773-781 | T50 | dementia | MentalOrBehavioralDysfunction | 773 | 781 | A4 | MEASUREMENTS: We performed neurologic examinations and reviewed medical records to investigate the effects of a clinical diagnosis of dementia and other potentially relevant factors on treatment with aspirin or warfarin at hospital discharge. | 633-893 | 633 | 893 | MEASUREMENTS: We performed neurologic examinations and reviewed medical records to investigate the @PREDICAT$ of a clinical diagnosis of @OBJECT$ and other potentially relevant factors on treatment with @SUBJECT$ or warfarin at hospital discharge. |
Uncommitted | preserve | 738-745 | 738-745 | T57 | effects | AFFECTS | 738 | 745 | preserve | 856-864 | 856-864 | T54 | warfarin | HazardousOrPoisonousSubstance | 856 | 864 | preserve | 773-781 | 773-781 | T50 | dementia | MentalOrBehavioralDysfunction | 773 | 781 | A5 | MEASUREMENTS: We performed neurologic examinations and reviewed medical records to investigate the effects of a clinical diagnosis of dementia and other potentially relevant factors on treatment with aspirin or warfarin at hospital discharge. | 633-893 | 633 | 893 | MEASUREMENTS: We performed neurologic examinations and reviewed medical records to investigate the @PREDICAT$ of a clinical diagnosis of @OBJECT$ and other potentially relevant factors on treatment with aspirin or @SUBJECT$ at hospital discharge. |
Fact | preserve | 1883-1887 | 1883-1887 | T129 | with | PROCESS_OF | 1,883 | 1,887 | preserve | 1888-1896 | 1888-1896 | T120 | dementia | MentalOrBehavioralDysfunction | 1,888 | 1,896 | preserve | 1874-1882 | 1874-1882 | T119 | patients | PatientOrDisabledGroup | 1,874 | 1,882 | A6 | The underutilization of aspirin and warfarin in older stroke patients with dementia may be a modifiable basis for their increased risk of recurrence and death. | 1807-1978 | 1,807 | 1,978 | The underutilization of aspirin and warfarin in older stroke @OBJECT$ @PREDICAT$ @SUBJECT$ may be a modifiable basis for their increased risk of recurrence and death. |
Fact | preserve | 180-183 | 180-183 | T18 | for | METHOD_OF | 180 | 183 | preserve | 170-179 | 170-179 | T12 | treatment | TherapeuticOrPreventiveProcedure | 170 | 179 | preserve | 194-214 | 204-214 | T13 | secondary prevention | TherapeuticOrPreventiveProcedure | 194 | 214 | A7 | OBJECTIVE: To investigate the influence of dementia status on treatment for the secondary prevention of stroke in older patients. | 108-243 | 108 | 243 | OBJECTIVE: To investigate the influence of dementia status on @SUBJECT$ @PREDICAT$ the @OBJECT$ of stroke in older patients. |
Fact | preserve | 1182-1186 | 1182-1186 | T102 | with | USES | 1,182 | 1,186 | preserve | 1169-1181 | 1169-1181 | T73 | nontreatment | HealthCareActivity | 1,169 | 1,181 | preserve | 1198-1206 | 1198-1206 | T75 | warfarin | HazardousOrPoisonousSubstance | 1,198 | 1,206 | A8 | Logistic regression determined that dementia (odds ratio (OR) = 2.57, 95% confidence interval (CI), 1.04-6.30) was a significant independent determinant of nontreatment with aspirin or warfarin, adjusting for abnormal gait (OR = 2.01, CI, .88-4.59); discharge to a nursing home or other institutional residence (OR = 2.55, CI, .83-7.81); cardiac disease (OR = .39, CI, .16-.95); cortical infarct location (OR = .45, CI, .18-1.10); male sex (OR = .47, CI, .20-1.15); age 80+ (OR = 1.14, CI, .46-2.82) and age 70-79 (OR = .96, CI, .32-2.88) versus age 60-69. | 1000-1600 | 1,000 | 1,600 | Logistic regression determined that dementia (odds ratio (OR) = 2.57, 95% confidence interval (CI), 1.04-6.30) was a significant independent determinant of @SUBJECT$ @PREDICAT$ aspirin or @OBJECT$ , adjusting for abnormal gait (OR = 2.01, CI, .88-4.59); discharge to a nursing home or other institutional residence (OR = 2.55, CI, .83-7.81); cardiac disease (OR = .39, CI, .16-.95); cortical infarct location (OR = .45, CI, .18-1.10); male sex (OR = .47, CI, .20-1.15); age 80+ (OR = 1.14, CI, .46-2.82) and age 70-79 (OR = .96, CI, .32-2.88) versus age 60-69. |
Fact | preserve | 1858-1860 | 1858-1860 | T127 | in | TREATS | 1,858 | 1,860 | preserve | 1849-1857 | 1849-1857 | T116 | warfarin | HazardousOrPoisonousSubstance | 1,849 | 1,857 | preserve | 1867-1873 | 1867-1873 | T118 | stroke | DiseaseOrSyndrome | 1,867 | 1,873 | A9 | The underutilization of aspirin and warfarin in older stroke patients with dementia may be a modifiable basis for their increased risk of recurrence and death. | 1807-1978 | 1,807 | 1,978 | The underutilization of aspirin and @SUBJECT$ @PREDICAT$ older @OBJECT$ patients with dementia may be a modifiable basis for their increased risk of recurrence and death. |
Fact | preserve | 451-453 | 451-453 | T36 | in | PROCESS_OF | 451 | 453 | preserve | 437-443 | 437-443 | T30 | stroke | DiseaseOrSyndrome | 437 | 443 | preserve | 460-468 | 460-468 | T32 | patients | PatientOrDisabledGroup | 460 | 468 | A10 | DESIGN: Based on patient examinations and medical record review, we investigated the frequency of aspirin and/or warfarin use at hospital discharge for the prevention of recurrent stroke in older patients hospitalized with acute ischemic stroke. | 244-509 | 244 | 509 | DESIGN: Based on patient examinations and medical record review, we investigated the frequency of aspirin and/or warfarin use at hospital discharge for the prevention of recurrent @SUBJECT$ @PREDICAT$ older @OBJECT$ hospitalized with acute ischemic stroke. |
Fact | preserve | 413-423 | 413-423 | T35 | prevention | PREVENTS | 413 | 423 | preserve | 348-355 | 348-355 | T23 | aspirin | OrganicChemical | 348 | 355 | preserve | 437-443 | 437-443 | T30 | stroke | DiseaseOrSyndrome | 437 | 443 | A11 | DESIGN: Based on patient examinations and medical record review, we investigated the frequency of aspirin and/or warfarin use at hospital discharge for the prevention of recurrent stroke in older patients hospitalized with acute ischemic stroke. | 244-509 | 244 | 509 | DESIGN: Based on patient examinations and medical record review, we investigated the frequency of @SUBJECT$ and/or warfarin use at hospital discharge for the @PREDICAT$ of recurrent @OBJECT$ in older patients hospitalized with acute ischemic stroke. |
Fact | preserve | 49-51 | 49-51 | T9 | in | PROCESS_OF | 49 | 51 | preserve | 42-48 | 42-48 | T3 | stroke | DiseaseOrSyndrome | 42 | 48 | preserve | 58-66 | 58-66 | T5 | patients | PatientOrDisabledGroup | 58 | 66 | A12 | Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. | 0-107 | 0 | 107 | Treatment for the secondary prevention of @SUBJECT$ @PREDICAT$ older @OBJECT$ : the influence of dementia status. |
Fact | preserve | 1858-1860 | 1858-1860 | T127 | in | TREATS | 1,858 | 1,860 | preserve | 1837-1844 | 1837-1844 | T115 | aspirin | OrganicChemical | 1,837 | 1,844 | preserve | 1867-1873 | 1867-1873 | T118 | stroke | DiseaseOrSyndrome | 1,867 | 1,873 | A13 | The underutilization of aspirin and warfarin in older stroke patients with dementia may be a modifiable basis for their increased risk of recurrence and death. | 1807-1978 | 1,807 | 1,978 | The underutilization of @SUBJECT$ and warfarin @PREDICAT$ older @OBJECT$ patients with dementia may be a modifiable basis for their increased risk of recurrence and death. |
Fact | preserve | 1711-1715 | 1711-1715 | T113 | with | USES | 1,711 | 1,715 | preserve | 1698-1710 | 1698-1710 | T107 | nontreatment | HealthCareActivity | 1,698 | 1,710 | preserve | 1716-1723 | 1716-1723 | T108 | aspirin | OrganicChemical | 1,716 | 1,723 | A14 | CONCLUSIONS: Our results suggest that dementia is a significant independent determinant of nontreatment with aspirin or warfarin when otherwise indicated for the prevention of recurrent stroke. | 1601-1806 | 1,601 | 1,806 | CONCLUSIONS: Our results suggest that dementia is a significant independent determinant of @SUBJECT$ @PREDICAT$ @OBJECT$ or warfarin when otherwise indicated for the prevention of recurrent stroke. |
Fact | preserve | 10-13 | 10-13 | T8 | for | METHOD_OF | 10 | 13 | preserve | 0-9 | 0-9 | T1 | Treatment | TherapeuticOrPreventiveProcedure | 0 | 9 | preserve | 18-38 | 28-38 | T2 | secondary prevention | TherapeuticOrPreventiveProcedure | 18 | 38 | A15 | Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. | 0-107 | 0 | 107 | @SUBJECT$ @PREDICAT$ the @OBJECT$ of stroke in older patients: the influence of dementia status. |
Fact | preserve | 1867-1882 | 1874-1882 | T126 | stroke patients | PROCESS_OF | 1,867 | 1,882 | preserve | 1867-1873 | 1867-1873 | T118 | stroke | DiseaseOrSyndrome | 1,867 | 1,873 | preserve | 1874-1882 | 1874-1882 | T119 | patients | PatientOrDisabledGroup | 1,874 | 1,882 | A16 | The underutilization of aspirin and warfarin in older stroke patients with dementia may be a modifiable basis for their increased risk of recurrence and death. | 1807-1978 | 1,807 | 1,978 | The underutilization of aspirin and warfarin in older @SUBJECT$ @PREDICAT$ @OBJECT$ with dementia may be a modifiable basis for their increased risk of recurrence and death. |
Fact | preserve | 1182-1186 | 1182-1186 | T102 | with | USES | 1,182 | 1,186 | preserve | 1169-1181 | 1169-1181 | T73 | nontreatment | HealthCareActivity | 1,169 | 1,181 | preserve | 1187-1194 | 1187-1194 | T74 | aspirin | OrganicChemical | 1,187 | 1,194 | A18 | Logistic regression determined that dementia (odds ratio (OR) = 2.57, 95% confidence interval (CI), 1.04-6.30) was a significant independent determinant of nontreatment with aspirin or warfarin, adjusting for abnormal gait (OR = 2.01, CI, .88-4.59); discharge to a nursing home or other institutional residence (OR = 2.55, CI, .83-7.81); cardiac disease (OR = .39, CI, .16-.95); cortical infarct location (OR = .45, CI, .18-1.10); male sex (OR = .47, CI, .20-1.15); age 80+ (OR = 1.14, CI, .46-2.82) and age 70-79 (OR = .96, CI, .32-2.88) versus age 60-69. | 1000-1600 | 1,000 | 1,600 | Logistic regression determined that dementia (odds ratio (OR) = 2.57, 95% confidence interval (CI), 1.04-6.30) was a significant independent determinant of @SUBJECT$ @PREDICAT$ @OBJECT$ or warfarin, adjusting for abnormal gait (OR = 2.01, CI, .88-4.59); discharge to a nursing home or other institutional residence (OR = 2.55, CI, .83-7.81); cardiac disease (OR = .39, CI, .16-.95); cortical infarct location (OR = .45, CI, .18-1.10); male sex (OR = .47, CI, .20-1.15); age 80+ (OR = 1.14, CI, .46-2.82) and age 70-79 (OR = .96, CI, .32-2.88) versus age 60-69. |
Fact | preserve | 225-227 | 225-227 | T19 | in | PROCESS_OF | 225 | 227 | preserve | 218-224 | 218-224 | T14 | stroke | DiseaseOrSyndrome | 218 | 224 | preserve | 234-242 | 234-242 | T16 | patients | PatientOrDisabledGroup | 234 | 242 | A19 | OBJECTIVE: To investigate the influence of dementia status on treatment for the secondary prevention of stroke in older patients. | 108-243 | 108 | 243 | OBJECTIVE: To investigate the influence of dementia status on treatment for the secondary prevention of @SUBJECT$ @PREDICAT$ older @OBJECT$ . |
Fact | preserve | 1858-1860 | 1858-1860 | T127 | in | TREATS | 1,858 | 1,860 | preserve | 1849-1857 | 1849-1857 | T116 | warfarin | HazardousOrPoisonousSubstance | 1,849 | 1,857 | preserve | 1888-1896 | 1888-1896 | T120 | dementia | MentalOrBehavioralDysfunction | 1,888 | 1,896 | A20 | The underutilization of aspirin and warfarin in older stroke patients with dementia may be a modifiable basis for their increased risk of recurrence and death. | 1807-1978 | 1,807 | 1,978 | The underutilization of aspirin and @SUBJECT$ @PREDICAT$ older stroke patients with @OBJECT$ may be a modifiable basis for their increased risk of recurrence and death. |
Fact | preserve | 1858-1860 | 1858-1860 | T127 | in | TREATS | 1,858 | 1,860 | preserve | 1837-1844 | 1837-1844 | T115 | aspirin | OrganicChemical | 1,837 | 1,844 | preserve | 1874-1882 | 1874-1882 | T119 | patients | PatientOrDisabledGroup | 1,874 | 1,882 | A21 | The underutilization of aspirin and warfarin in older stroke patients with dementia may be a modifiable basis for their increased risk of recurrence and death. | 1807-1978 | 1,807 | 1,978 | The underutilization of @SUBJECT$ and warfarin @PREDICAT$ older stroke @OBJECT$ with dementia may be a modifiable basis for their increased risk of recurrence and death. |
Fact | preserve | 2166-2168 | 2166-2168 | T148 | in | TREATS | 2,166 | 2,168 | preserve | 2144-2165 | 2161-2165 | T137 | antihypertensive drug | PharmacologicSubstance | 2,144 | 2,165 | preserve | 2175-2183 | 2175-2183 | T139 | patients | PatientOrDisabledGroup | 2,175 | 2,183 | A1 | Nifedipine is an effective antihypertensive drug in NIDDM patients and its action may be in part related to a decrease in pressor response to norepinephrine and angiotensin II. | 2111-2300 | 2,111 | 2,300 | Nifedipine is an effective @SUBJECT$ @PREDICAT$ NIDDM @OBJECT$ and its action may be in part related to a decrease in pressor response to norepinephrine and angiotensin II. |
Fact | preserve | 2111-2165 | 2161-2165 | T146 | Nifedipine is an effective antihypertensive drug | ISA | 2,111 | 2,165 | preserve | 2111-2121 | 2111-2121 | T135 | Nifedipine | OrganicChemical | 2,111 | 2,121 | preserve | 2144-2165 | 2161-2165 | T137 | antihypertensive drug | PharmacologicSubstance | 2,144 | 2,165 | A3 | Nifedipine is an effective antihypertensive drug in NIDDM patients and its action may be in part related to a decrease in pressor response to norepinephrine and angiotensin II. | 2111-2300 | 2,111 | 2,300 | @SUBJECT$ @PREDICAT$ @OBJECT$ in NIDDM patients and its action may be in part related to a decrease in pressor response to norepinephrine and angiotensin II. |
Fact | preserve | 2169-2183 | 2175-2183 | T147 | NIDDM patients | PROCESS_OF | 2,169 | 2,183 | preserve | 2169-2174 | 2169-2174 | T138 | NIDDM | DiseaseOrSyndrome | 2,169 | 2,174 | preserve | 2175-2183 | 2175-2183 | T139 | patients | PatientOrDisabledGroup | 2,175 | 2,183 | A4 | Nifedipine is an effective antihypertensive drug in NIDDM patients and its action may be in part related to a decrease in pressor response to norepinephrine and angiotensin II. | 2111-2300 | 2,111 | 2,300 | Nifedipine is an effective antihypertensive drug in @SUBJECT$ @PREDICAT$ @OBJECT$ and its action may be in part related to a decrease in pressor response to norepinephrine and angiotensin II. |
Fact | preserve | 54-75 | 67-75 | T7 | hypertensive patients | PROCESS_OF | 54 | 75 | preserve | 54-66 | 54-66 | T4 | hypertensive | Finding | 54 | 66 | preserve | 67-75 | 67-75 | T5 | patients | PatientOrDisabledGroup | 67 | 75 | A5 | Dietary salt intake, blood pressure and the kidney in hypertensive patients with non-insulin dependent diabetes mellitus. | 0-128 | 0 | 128 | Dietary salt intake, blood pressure and the kidney in @SUBJECT$ @PREDICAT$ @OBJECT$ with non-insulin dependent diabetes mellitus. |
Fact | preserve | 1411-1420 | 1411-1420 | T100 | decreased | INHIBITS | 1,411 | 1,420 | preserve | 1400-1410 | 1400-1410 | T89 | Nifedipine | OrganicChemical | 1,400 | 1,410 | preserve | 1421-1435 | 1427-1435 | T90 | blood pressure | Finding | 1,421 | 1,435 | A7 | Nifedipine decreased blood pressure equally in salt-sensitive and salt-resistant hypertensive patients and during the high and the low salt intake. | 1400-1554 | 1,400 | 1,554 | @SUBJECT$ @PREDICAT$ @OBJECT$ equally in salt-sensitive and salt-resistant hypertensive patients and during the high and the low salt intake. |
Fact | preserve | 176-190 | 182-190 | T14 | NIDDM patients | PROCESS_OF | 176 | 190 | preserve | 176-181 | 176-181 | T12 | NIDDM | DiseaseOrSyndrome | 176 | 181 | preserve | 182-190 | 182-190 | T13 | patients | PatientOrDisabledGroup | 182 | 190 | A10 | The mechanisms responsible for hypertension in NIDDM patients are only partially understood. | 129-228 | 129 | 228 | The mechanisms responsible for hypertension in @SUBJECT$ @PREDICAT$ @OBJECT$ are only partially understood. |
Fact | preserve | 76-80 | 76-80 | T9 | with | PROCESS_OF | 76 | 80 | preserve | 88-127 | 119-127 | T6 | non-insulin dependent diabetes mellitus | DiseaseOrSyndrome | 88 | 127 | preserve | 67-75 | 67-75 | T5 | patients | PatientOrDisabledGroup | 67 | 75 | A11 | Dietary salt intake, blood pressure and the kidney in hypertensive patients with non-insulin dependent diabetes mellitus. | 0-128 | 0 | 128 | Dietary salt intake, blood pressure and the kidney in hypertensive @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 935-937 | 935-937 | T55 | in | PROCESS_OF | 935 | 937 | preserve | 889-903 | 895-903 | T52 | blood pressure | Finding | 889 | 903 | preserve | 944-952 | 944-952 | T54 | patients | PatientOrDisabledGroup | 944 | 952 | A12 | High salt intake increased blood pressure and decreased heart rate in these patients. | 862-953 | 862 | 953 | High salt intake increased @SUBJECT$ and decreased heart rate @PREDICAT$ these @OBJECT$ . |
Fact | preserve | 935-937 | 935-937 | T55 | in | PROCESS_OF | 935 | 937 | preserve | 914-934 | 930-934 | T53 | decreased heart rate | Finding | 914 | 934 | preserve | 944-952 | 944-952 | T54 | patients | PatientOrDisabledGroup | 944 | 952 | A13 | High salt intake increased blood pressure and decreased heart rate in these patients. | 862-953 | 862 | 953 | High salt intake increased blood pressure and @SUBJECT$ @PREDICAT$ these @OBJECT$ . |
Fact | preserve | 1572-1581 | 1572-1581 | T111 | increased | AUGMENTS | 1,572 | 1,581 | preserve | 1555-1565 | 1555-1565 | T101 | Nifedipine | OrganicChemical | 1,555 | 1,565 | preserve | 1582-1598 | 1594-1598 | T102 | renal blood flow | OrganOrTissueFunction | 1,582 | 1,598 | A14 | Nifedipine increased renal blood flow, both in salt-sensitive and in salt-resistant individuals, but the differences did not reach statistical significance. | 1555-1723 | 1,555 | 1,723 | @SUBJECT$ @PREDICAT$ @OBJECT$ , both in salt-sensitive and in salt-resistant individuals, but the differences did not reach statistical significance. |
Fact | preserve | 173-175 | 173-175 | T15 | in | PROCESS_OF | 173 | 175 | preserve | 160-172 | 160-172 | T11 | hypertension | DiseaseOrSyndrome | 160 | 172 | preserve | 182-190 | 182-190 | T13 | patients | PatientOrDisabledGroup | 182 | 190 | A16 | The mechanisms responsible for hypertension in NIDDM patients are only partially understood. | 129-228 | 129 | 228 | The mechanisms responsible for @SUBJECT$ @PREDICAT$ NIDDM @OBJECT$ are only partially understood. |
Fact | preserve | 2111-2165 | 2161-2165 | T149 | Nifedipine is an effective antihypertensive drug | TREATS | 2,111 | 2,165 | preserve | 2111-2121 | 2111-2121 | T135 | Nifedipine | OrganicChemical | 2,111 | 2,121 | preserve | 2175-2183 | 2175-2183 | T139 | patients | PatientOrDisabledGroup | 2,175 | 2,183 | A17 | Nifedipine is an effective antihypertensive drug in NIDDM patients and its action may be in part related to a decrease in pressor response to norepinephrine and angiotensin II. | 2111-2300 | 2,111 | 2,300 | @SUBJECT$ @PREDICAT$ in NIDDM @OBJECT$ and its action may be in part related to a decrease in pressor response to norepinephrine and angiotensin II. |
Fact | preserve | 244-272 | 265-272 | T29 | prednisone (20 mg/d) therapy | ISA | 244 | 272 | preserve | 244-254 | 244-254 | T16 | prednisone | Hormone | 244 | 254 | preserve | 265-272 | 265-272 | T17 | therapy | TherapeuticOrPreventiveProcedure | 265 | 272 | A1 | METHODS: Changes of serum levels of soluble interleukin-2 receptor (sIL-2R) after oral prednisone (20 mg/d) therapy were observed, and the peripheral blood T cell inhibitory effects of dexamethasone, oxymatrine and thymus-derived immunoinhibiting agents were studied in vitro by lymphocyte proliferation assay. | 151-485 | 151 | 485 | METHODS: Changes of serum levels of soluble interleukin-2 receptor (sIL-2R) after oral @SUBJECT$ @PREDICAT$ @OBJECT$ were observed, and the peripheral blood T cell inhibitory effects of dexamethasone, oxymatrine and thymus-derived immunoinhibiting agents were studied in vitro by lymphocyte proliferation assay. |
Fact | preserve | 916-925 | 916-925 | T73 | inhibited | DISRUPTS | 916 | 925 | preserve | 855-865 | 855-865 | T63 | Oxymatrine | PharmacologicSubstance | 855 | 865 | preserve | 926-946 | 933-946 | T66 | T cell proliferation | CellFunction | 926 | 946 | A3 | Oxymatrine and thymus-derived immuno-inhibiting agents inhibited T cell proliferation to a similar degree between SR and SS asthmatics. | 855-1002 | 855 | 1,002 | @SUBJECT$ and thymus-derived immuno-inhibiting agents @PREDICAT$ @OBJECT$ to a similar degree between SR and SS asthmatics. |
Fact | preserve | 501-519 | 512-519 | T46 | prednisone therapy | ISA | 501 | 519 | preserve | 501-511 | 501-511 | T33 | prednisone | Hormone | 501 | 511 | preserve | 512-519 | 512-519 | T34 | therapy | TherapeuticOrPreventiveProcedure | 512 | 519 | A4 | RESULTS: After prednisone therapy, serum levels of sIL-2R were significantly decreased in steroid-sensitive (SS) asthmatics (P < 0.001) but not in SR asthmatics (P > 0.5). | 486-669 | 486 | 669 | RESULTS: After @SUBJECT$ @PREDICAT$ @OBJECT$ , serum levels of sIL-2R were significantly decreased in steroid-sensitive (SS) asthmatics (P < 0.001) but not in SR asthmatics (P > 0.5). |
Fact | preserve | 1240-1250 | 1240-1250 | T93 | management | TREATS | 1,240 | 1,250 | preserve | 1217-1232 | 1217-1232 | T86 | glucocorticoids | Hormone | 1,217 | 1,232 | preserve | 1257-1263 | 1257-1263 | T90 | asthma | DiseaseOrSyndrome | 1,257 | 1,263 | A8 | The therapeutic benefit of immuno-inhibiting agents other than glucocorticoids in the management of SR asthma deserves further investigation. | 1148-1295 | 1,148 | 1,295 | The therapeutic benefit of immuno-inhibiting agents other than @SUBJECT$ in the @PREDICAT$ of SR @OBJECT$ deserves further investigation. |
Fact | preserve | 501-519 | 512-519 | T47 | prednisone therapy | USES | 501 | 519 | preserve | 512-519 | 512-519 | T34 | therapy | TherapeuticOrPreventiveProcedure | 512 | 519 | preserve | 501-511 | 501-511 | T33 | prednisone | Hormone | 501 | 511 | A10 | RESULTS: After prednisone therapy, serum levels of sIL-2R were significantly decreased in steroid-sensitive (SS) asthmatics (P < 0.001) but not in SR asthmatics (P > 0.5). | 486-669 | 486 | 669 | RESULTS: After @OBJECT$ @PREDICAT$ @SUBJECT$ , serum levels of sIL-2R were significantly decreased in steroid-sensitive (SS) asthmatics (P < 0.001) but not in SR asthmatics (P > 0.5). |
Fact | preserve | 159-177 | 167-177 | T16 | aerosol medication | ADMINISTERED_TO | 159 | 177 | preserve | 159-166 | 159-166 | T10 | aerosol | ChemicalViewedStructurally | 159 | 166 | preserve | 98-106 | 98-106 | T7 | patients | PatientOrDisabledGroup | 98 | 106 | A1 | Pharmacists should ensure that patients with asthma know how to use their pressurized aerosol medication, including bronchodilators and steroids. | 67-218 | 67 | 218 | Pharmacists should ensure that @OBJECT$ with asthma know how to use their pressurized @SUBJECT$ @PREDICAT$ , including bronchodilators and steroids. |
Fact | preserve | 55-58 | 55-58 | T5 | for | TREATS | 55 | 58 | preserve | 46-54 | 46-54 | T3 | aerosols | ChemicalViewedStructurally | 46 | 54 | preserve | 59-65 | 59-65 | T4 | asthma | DiseaseOrSyndrome | 59 | 65 | A3 | Pharmacist's role when dispensing pressurized aerosols for asthma. | 0-66 | 0 | 66 | Pharmacist's role when dispensing pressurized @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 131-134 | 131-134 | T15 | use | ADMINISTERED_TO | 131 | 134 | preserve | 167-177 | 167-177 | T11 | medication | PharmacologicSubstance | 167 | 177 | preserve | 98-106 | 98-106 | T7 | patients | PatientOrDisabledGroup | 98 | 106 | A4 | Pharmacists should ensure that patients with asthma know how to use their pressurized aerosol medication, including bronchodilators and steroids. | 67-218 | 67 | 218 | Pharmacists should ensure that @OBJECT$ with asthma know how to @PREDICAT$ their pressurized aerosol @SUBJECT$ , including bronchodilators and steroids. |
Fact | preserve | 776-784 | 776-784 | T54 | combined | COEXISTS_WITH | 776 | 784 | preserve | 796-814 | 809-814 | T52 | antidiabetic drugs | PharmacologicSubstance | 796 | 814 | preserve | 636-648 | 636-648 | T49 | troglitazone | OrganicChemical | 636 | 648 | A2 | The antihyperglycemic effect of troglitazone as monotherapy is rather modest (reduction of HbA1c by 0.5-1.0%), but it appears to be somewhat greater when it is combined with other antidiabetic drugs. | 598-815 | 598 | 815 | The antihyperglycemic effect of @OBJECT$ as monotherapy is rather modest (reduction of HbA1c by 0.5-1.0%), but it appears to be somewhat greater when it is @PREDICAT$ with other @SUBJECT$ . |
Fact | preserve | 444-451 | 444-451 | T34 | treated | TREATS | 444 | 451 | preserve | 469-482 | 469-482 | T30 | sulfonylureas | OrganicChemical | 469 | 482 | preserve | 420-428 | 420-428 | T27 | diabetic | Finding | 420 | 428 | A3 | Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 diabetic patients treated with diet alone, sulfonylureas, or insulin. | 300-495 | 300 | 495 | Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 @OBJECT$ patients @PREDICAT$ with diet alone, @SUBJECT$ , or insulin. |
Fact | preserve | 444-451 | 444-451 | T34 | treated | TREATS | 444 | 451 | preserve | 487-494 | 487-494 | T31 | insulin | AminoAcidPeptideOrProtein | 487 | 494 | preserve | 420-428 | 420-428 | T27 | diabetic | Finding | 420 | 428 | A4 | Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 diabetic patients treated with diet alone, sulfonylureas, or insulin. | 300-495 | 300 | 495 | Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 @OBJECT$ patients @PREDICAT$ with diet alone, sulfonylureas, or @SUBJECT$ . |
Fact | preserve | 444-451 | 444-451 | T34 | treated | TREATS | 444 | 451 | preserve | 487-494 | 487-494 | T31 | insulin | AminoAcidPeptideOrProtein | 487 | 494 | preserve | 429-437 | 429-437 | T28 | patients | PatientOrDisabledGroup | 429 | 437 | A8 | Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 diabetic patients treated with diet alone, sulfonylureas, or insulin. | 300-495 | 300 | 495 | Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 diabetic @OBJECT$ @PREDICAT$ with diet alone, sulfonylureas, or @SUBJECT$ . |
Fact | preserve | 1168-1185 | 1177-1185 | T72 | diabetic patients | PROCESS_OF | 1,168 | 1,185 | preserve | 1168-1176 | 1168-1176 | T69 | diabetic | Finding | 1,168 | 1,176 | preserve | 1177-1185 | 1177-1185 | T70 | patients | PatientOrDisabledGroup | 1,177 | 1,185 | A11 | It may be considered as a valuable alternative in insulin-resistant (obese and hyperinsulinemic) diabetic patients who appear to be the best responders to the drug. | 1065-1241 | 1,065 | 1,241 | It may be considered as a valuable alternative in insulin-resistant (obese and hyperinsulinemic) @SUBJECT$ @PREDICAT$ @OBJECT$ who appear to be the best responders to the drug. |
Fact | preserve | 420-437 | 429-437 | T32 | diabetic patients | PROCESS_OF | 420 | 437 | preserve | 420-428 | 420-428 | T27 | diabetic | Finding | 420 | 428 | preserve | 429-437 | 429-437 | T28 | patients | PatientOrDisabledGroup | 429 | 437 | A13 | Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 diabetic patients treated with diet alone, sulfonylureas, or insulin. | 300-495 | 300 | 495 | Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 @SUBJECT$ @PREDICAT$ @OBJECT$ treated with diet alone, sulfonylureas, or insulin. |
Fact | preserve | 444-451 | 444-451 | T34 | treated | TREATS | 444 | 451 | preserve | 469-482 | 469-482 | T30 | sulfonylureas | OrganicChemical | 469 | 482 | preserve | 429-437 | 429-437 | T28 | patients | PatientOrDisabledGroup | 429 | 437 | A15 | Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 diabetic patients treated with diet alone, sulfonylureas, or insulin. | 300-495 | 300 | 495 | Troglitazone exerts an antihyperglycemic activity in a dose-dependent manner between 200 and 600 mg/day in type 2 diabetic @OBJECT$ @PREDICAT$ with diet alone, @SUBJECT$ , or insulin. |
Fact | preserve | 303-313 | 303-313 | T26 | prevention | PREVENTS | 303 | 313 | preserve | 265-275 | 265-275 | T17 | Raloxifene | OrganicChemical | 265 | 275 | preserve | 317-329 | 317-329 | T20 | osteoporosis | DiseaseOrSyndrome | 317 | 329 | A1 | Raloxifene is available for the prevention of osteoporosis, and preliminary studies show a decrease in breast cancer risk. | 265-399 | 265 | 399 | @SUBJECT$ is available for the @PREDICAT$ of @OBJECT$ , and preliminary studies show a decrease in breast cancer risk. |
Fact | preserve | 49-107 | 98-107 | T15 | Tamoxifen, the first selective estrogen receptor modulator | ISA | 49 | 107 | preserve | 49-58 | 49-58 | T5 | Tamoxifen | OrganicChemical | 49 | 58 | preserve | 70-107 | 98-107 | T7 | selective estrogen receptor modulator | PharmacologicSubstance | 70 | 107 | A2 | Tamoxifen, the first selective estrogen receptor modulator (SERM), has provided invaluable laboratory and clinical evidence that such drugs can reduce the risk of breast cancer and increase bone density. | 49-264 | 49 | 264 | @SUBJECT$ @PREDICAT$ @OBJECT$ (SERM), has provided invaluable laboratory and clinical evidence that such drugs can reduce the risk of breast cancer and increase bone density. |
Fact | preserve | 26-33 | 26-33 | T4 | Prevent | PREVENTS | 26 | 33 | preserve | 9-22 | 9-22 | T2 | Antiestrogens | PharmacologicSubstance | 9 | 22 | preserve | 34-47 | 41-47 | T3 | Breast Cancer | NeoplasticProcess | 34 | 47 | A3 | Targeted Antiestrogens to Prevent Breast Cancer. | 0-48 | 0 | 48 | Targeted @SUBJECT$ to @PREDICAT$ @OBJECT$ . |
Probable | preserve | 199-214 | 210-214 | T16 | reduce the risk | PREVENTS | 199 | 214 | preserve | 189-194 | 189-194 | T10 | drugs | PharmacologicSubstance | 189 | 194 | preserve | 224-237 | 231-237 | T12 | breast cancer | NeoplasticProcess | 224 | 237 | A4 | Tamoxifen, the first selective estrogen receptor modulator (SERM), has provided invaluable laboratory and clinical evidence that such drugs can reduce the risk of breast cancer and increase bone density. | 49-264 | 49 | 264 | Tamoxifen, the first selective estrogen receptor modulator (SERM), has provided invaluable laboratory and clinical evidence that such @SUBJECT$ can @PREDICAT$ of @OBJECT$ and increase bone density. |
Probable | preserve | 1383-1390 | 1383-1390 | T82 | control | TREATS | 1,383 | 1,390 | preserve | 1337-1346 | 1337-1346 | T77 | treatment | TherapeuticOrPreventiveProcedure | 1,337 | 1,346 | preserve | 1394-1400 | 1394-1400 | T81 | asthma | DiseaseOrSyndrome | 1,394 | 1,400 | A2 | Clinical experience has shown that early diagnosis and treatment of GERD often leads to better control of asthma. | 1276-1401 | 1,276 | 1,401 | Clinical experience has shown that early diagnosis and @SUBJECT$ of GERD often leads to better @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 472-476 | 472-476 | T27 | with | PROCESS_OF | 472 | 476 | preserve | 477-483 | 477-483 | T25 | asthma | DiseaseOrSyndrome | 477 | 483 | preserve | 463-471 | 463-471 | T24 | patients | PatientOrDisabledGroup | 463 | 471 | A6 | GERD, a common disorder of infancy, old age, and pregnancy, is particularly prevalent in patients with asthma. | 368-484 | 368 | 484 | GERD, a common disorder of infancy, old age, and pregnancy, is particularly prevalent in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 686-691 | 686-691 | T39 | treat | TREATS | 686 | 691 | preserve | 666-677 | 666-677 | T36 | medications | PharmacologicSubstance | 666 | 677 | preserve | 699-705 | 699-705 | T37 | asthma | DiseaseOrSyndrome | 699 | 705 | A8 | The physiologic changes of asthma exacerbations and the actions of some of the medications used to treat asthma both aggravate GERD. | 581-726 | 581 | 726 | The physiologic changes of asthma exacerbations and the actions of some of the @SUBJECT$ used to @PREDICAT$ @OBJECT$ both aggravate GERD. |
Fact | preserve | 877-883 | 877-883 | T54 | result | CAUSES | 877 | 883 | preserve | 815-836 | 824-836 | T46 | appetite suppressants | PharmacologicSubstance | 815 | 836 | preserve | 887-904 | 900-904 | T49 | weight loss | Finding | 887 | 904 | A3 | phenyl-propanolamine, phentermine) result in weight loss but stimulatory effects limit their use. | 842-945 | 842 | 945 | phenyl-propanolamine, phentermine) result in weight loss but stimulato @SUBJECT$ @PREDICAT$ in @OBJECT$ but stimulatory effects limit their use. |
Probable | preserve | 2549-2555 | 2549-2555 | T146 | result | CAUSES | 2,549 | 2,555 | preserve | 2526-2544 | 2538-2544 | T137 | Weight loss agents | PharmacologicSubstance | 2,526 | 2,544 | preserve | 2573-2584 | 2580-2584 | T139 | weight loss | Finding | 2,573 | 2,584 | A4 | Weight loss agents may result in initial weight loss, but sustained weight loss is not always achieved even with continuation of treatment. | 2526-2677 | 2,526 | 2,677 | @SUBJECT$ may @PREDICAT$ in initial @OBJECT$ , but sustained weight loss is not always achieved even with continuation of treatment. |
Fact | preserve | 1307-1315 | 1307-1315 | T72 | presence | COEXISTS_WITH | 1,307 | 1,315 | preserve | 1272-1279 | 1272-1279 | T70 | obesity | DiseaseOrSyndrome | 1,272 | 1,279 | preserve | 1325-1352 | 1345-1352 | T71 | cardiovascular risk factors | DiseaseOrSyndrome | 1,325 | 1,352 | A5 | The combination noradrenergic/serotonergic agent sibutramine is indicated for the management of obesity, particularly in the presence of other cardiovascular risk factors. | 1170-1353 | 1,170 | 1,353 | The combination noradrenergic/serotonergic agent sibutramine is indicated for the management of @SUBJECT$ , particularly in the @PREDICAT$ of other @OBJECT$ . |
Fact | preserve | 950-989 | 977-989 | T64 | serotonergic agents (fenfluramine | ISA | 950 | 989 | preserve | 977-989 | 977-989 | T57 | fenfluramine | OrganicChemical | 977 | 989 | preserve | 950-969 | 963-969 | T56 | serotonergic agents | NeuroreactiveSubstanceOrBiogenicAmine | 950 | 969 | A6 | The serotonergic agents (fenfluramine, dexfenfluramine) were effective weight loss drugs, but were voluntarily withdrawn from the US market last year because of cardiovascular and pulmonary complications. | 946-1169 | 946 | 1,169 | The @OBJECT$ @PREDICAT$ @SUBJECT$ , dexfenfluramine) were effective weight loss drugs, but were voluntarily withdrawn from the US market last year because of cardiovascular and pulmonary complications. |
Fact | preserve | 445-451 | 445-448 | T30 | due to | CAUSES | 445 | 451 | preserve | 455-464 | 455-464 | T27 | imbalance | SignOrSymptom | 455 | 464 | preserve | 395-402 | 395-402 | T23 | Obesity | DiseaseOrSyndrome | 395 | 402 | A7 | Obesity is a multifactorial condition, most often due to an imbalance in energy intake and expenditure. | 395-504 | 395 | 504 | @OBJECT$ is a multifactorial condition, most often @PREDICAT$ an @SUBJECT$ in energy intake and expenditure. |
Fact | preserve | 163-173 | 163-173 | T14 | treatments | TREATS | 163 | 173 | preserve | 67-93 | 83-93 | T5 | pharmacological management | HealthCareActivity | 67 | 93 | preserve | 151-162 | 158-162 | T9 | weight loss | Finding | 151 | 162 | A8 | The pharmacological management of obesity has gained increasing attention as new weight loss treatments are approved and a significant proportion of the public strives to lose weight. | 63-259 | 63 | 259 | The @SUBJECT$ of obesity has gained increasing attention as new @OBJECT$ @PREDICAT$ are approved and a significant proportion of the public strives to lose weight. |
Fact | preserve | 815-862 | 842-862 | T53 | appetite suppressants (ie. phenyl-propanolamine | ISA | 815 | 862 | preserve | 842-862 | 842-862 | T47 | phenyl-propanolamine | OrganicChemical | 842 | 862 | preserve | 815-836 | 824-836 | T46 | appetite suppressants | PharmacologicSubstance | 815 | 836 | A9 | Current concepts in the pharmacological management of obesity. | 0-62 | 0 | 62 | Current concepts in the pharmacological management of obesity. @OBJECT$ @PREDICAT$ @SUBJECT$ |
Fact | preserve | 2504-2513 | 2504-2513 | T136 | treatment | TREATS | 2,504 | 2,513 | preserve | 2489-2496 | 2489-2496 | T133 | regimen | ResearchActivity | 2,489 | 2,496 | preserve | 2517-2524 | 2517-2524 | T135 | obesity | DiseaseOrSyndrome | 2,517 | 2,524 | A10 | Pharmacological agents should be used as an aid to a structured diet and exercise regimen in the treatment of obesity. | 2401-2525 | 2,401 | 2,525 | Pharmacological agents should be used as an aid to a structured diet and exercise @SUBJECT$ in the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 815-862 | 842-862 | T55 | appetite suppressants (ie. phenyl-propanolamine | CAUSES | 815 | 862 | preserve | 842-862 | 842-862 | T47 | phenyl-propanolamine | OrganicChemical | 842 | 862 | preserve | 887-904 | 900-904 | T49 | weight loss | Finding | 887 | 904 | A11 | Current concepts in the pharmacological management of obesity. | 0-62 | 0 | 62 | Current concepts in the pharmacological management of obesity. @PREDICAT$ @SUBJECT$ @OBJECT$ |
Fact | preserve | 1056-1059 | 1056-1059 | T58 | for | TREATS | 1,056 | 1,059 | preserve | 1037-1055 | 1050-1055 | T55 | antidiabetic drugs | PharmacologicSubstance | 1,037 | 1,055 | preserve | 1060-1075 | 1067-1075 | T56 | type 2 diabetes | DiseaseOrSyndrome | 1,060 | 1,075 | A1 | Troglitazone is a valuable addition to the arsenal of antidiabetic drugs for type 2 diabetes. | 977-1076 | 977 | 1,076 | Troglitazone is a valuable addition to the arsenal of @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 977-1055 | 1020-1027 | T59 | Troglitazone is a valuable addition to the arsenal of antidiabetic drugs | TREATS | 977 | 1,055 | preserve | 977-989 | 977-989 | T52 | Troglitazone | OrganicChemical | 977 | 989 | preserve | 1060-1075 | 1067-1075 | T56 | type 2 diabetes | DiseaseOrSyndrome | 1,060 | 1,075 | A2 | Troglitazone is a valuable addition to the arsenal of antidiabetic drugs for type 2 diabetes. | 977-1076 | 977 | 1,076 | @SUBJECT$ @PREDICAT$ for @OBJECT$ . |
Fact | preserve | 566-568 | 566-568 | T34 | in | PROCESS_OF | 566 | 568 | preserve | 548-565 | 554-565 | T31 | liver dysfunction | PathologicFunction | 548 | 565 | preserve | 574-582 | 574-582 | T32 | patients | PatientOrDisabledGroup | 574 | 582 | A3 | Recently, however, it became clear that troglitazone could cause liver dysfunction in some patients. | 477-583 | 477 | 583 | Recently, however, it became clear that troglitazone could cause @SUBJECT$ @PREDICAT$ some @OBJECT$ . |
Fact | preserve | 977-1055 | 1020-1027 | T57 | Troglitazone is a valuable addition to the arsenal of antidiabetic drugs | ISA | 977 | 1,055 | preserve | 977-989 | 977-989 | T52 | Troglitazone | OrganicChemical | 977 | 989 | preserve | 1037-1055 | 1050-1055 | T55 | antidiabetic drugs | PharmacologicSubstance | 1,037 | 1,055 | A4 | Troglitazone is a valuable addition to the arsenal of antidiabetic drugs for type 2 diabetes. | 977-1076 | 977 | 1,076 | @SUBJECT$ @PREDICAT$ @OBJECT$ for type 2 diabetes. |
Fact | preserve | 855-857 | 855-857 | T48 | on | LOCATION_OF | 855 | 857 | preserve | 868-873 | 868-873 | T46 | liver | BodyPartOrganOrOrganComponent | 868 | 873 | preserve | 842-854 | 847-854 | T45 | side effects | PathologicFunction | 842 | 854 | A5 | Troglitazone was to be introduced in Europe in 1998 but registration procedures and clinical trials have been stopped because of its side effects on the liver. | 703-874 | 703 | 874 | Troglitazone was to be introduced in Europe in 1998 but registration procedures and clinical trials have been stopped because of its @OBJECT$ @PREDICAT$ the @SUBJECT$ . |
Fact | preserve | 313-321 | 313-321 | T22 | lowering | INHIBITS | 313 | 321 | preserve | 289-301 | 289-301 | T17 | Troglitazone | OrganicChemical | 289 | 301 | preserve | 346-359 | 346-359 | T21 | triglycerides | BiologicallyActiveSubstance | 346 | 359 | A6 | Troglitazone also has a lowering effect on the levels of triglycerides. | 289-360 | 289 | 360 | @SUBJECT$ also has a @PREDICAT$ effect on the levels of @OBJECT$ . |
Fact | preserve | 174-182 | 174-182 | T13 | enhances | AUGMENTS | 174 | 182 | preserve | 150-162 | 150-162 | T10 | Troglitazone | OrganicChemical | 150 | 162 | preserve | 200-219 | 208-219 | T12 | insulin sensitivity | PathologicFunction | 200 | 219 | A7 | Troglitazone indirectly enhances peripheral insulin sensitivity. | 150-220 | 150 | 220 | @SUBJECT$ indirectly @PREDICAT$ peripheral @OBJECT$ . |
Possible | preserve | 542-547 | 542-547 | T33 | cause | CAUSES | 542 | 547 | preserve | 523-535 | 523-535 | T30 | troglitazone | OrganicChemical | 523 | 535 | preserve | 548-565 | 554-565 | T31 | liver dysfunction | PathologicFunction | 548 | 565 | A8 | Recently, however, it became clear that troglitazone could cause liver dysfunction in some patients. | 477-583 | 477 | 583 | Recently, however, it became clear that @SUBJECT$ could @PREDICAT$ @OBJECT$ in some patients. |
Fact | preserve | 1260-1264 | 1260-1264 | T74 | risk | PREDISPOSES | 1,260 | 1,264 | preserve | 1322-1334 | 1322-1334 | T70 | troglitazone | OrganicChemical | 1,322 | 1,334 | preserve | 1275-1298 | 1287-1298 | T69 | liver dysfunction | PathologicFunction | 1,275 | 1,298 | A9 | The risk of severe liver dysfunction is a reason to reserve troglitazone as a second-line drug. | 1256-1357 | 1,256 | 1,357 | The @PREDICAT$ of severe @OBJECT$ is a reason to reserve @SUBJECT$ as a second-line drug. |
Uncommitted | preserve | 1060-1062 | 1060-1062 | T76 | in | ASSOCIATED_WITH | 1,060 | 1,062 | preserve | 1026-1030 | 1026-1030 | T71 | VEGF | AminoAcidPeptideOrProtein | 1,026 | 1,030 | preserve | 1067-1080 | 1075-1080 | T73 | primary tumor | NeoplasticProcess | 1,067 | 1,080 | A4 | The cytosolic levels of VEGF and TP were determined in the primary tumor by original immunometric methods. | 1002-1114 | 1,002 | 1,114 | The cytosolic levels of @SUBJECT$ and TP were determined @PREDICAT$ the @OBJECT$ by original immunometric methods. |
Fact | preserve | 3642-3649 | 3642-3649 | T240 | treated | TREATS | 3,642 | 3,649 | preserve | 3664-3673 | 3664-3673 | T233 | tamoxifen | OrganicChemical | 3,664 | 3,673 | preserve | 3637-3641 | 3637-3641 | T231 | NPBC | NeoplasticProcess | 3,637 | 3,641 | A7 | Low levels of VEGF and the presence of less than three involved axillary nodes characterize the patients with NPBC treated with adjuvant tamoxifen who have the highest likelihood of favorable outcome. | 3521-3734 | 3,521 | 3,734 | Low levels of VEGF and the presence of less than three involved axillary nodes characterize the patients with @OBJECT$ @PREDICAT$ with adjuvant @SUBJECT$ who have the highest likelihood of favorable outcome. |
Fact | preserve | 651-658 | 651-658 | T47 | treated | TREATS | 651 | 658 | preserve | 671-692 | 680-692 | T37 | adjuvant chemotherapy | TherapeuticOrPreventiveProcedure | 671 | 692 | preserve | 630-643 | 637-643 | T36 | breast cancer | NeoplasticProcess | 630 | 643 | A8 | PURPOSE: To determine the role of the two angiogenic peptides, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) (the latter also being a target enzyme for cytotoxicity of 5-fluorouracil and methotrexate), and conventional prognostic factors in predicting relapse-free survival (RFS) and overall survival (OS) probabilities in two cohorts of patients with node-positive breast cancer (NPBC) treated with either adjuvant chemotherapy (CMF [cyclophosphamide, methotrexate, 5-fluorouracil] schedule) or hormone therapy (tamoxifen). | 204-800 | 204 | 800 | PURPOSE: To determine the role of the two angiogenic peptides, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) (the latter also being a target enzyme for cytotoxicity of 5-fluorouracil and methotrexate), and conventional prognostic factors in predicting relapse-free survival (RFS) and overall survival (OS) probabilities in two cohorts of patients with node-positive @OBJECT$ (NPBC) @PREDICAT$ with either @SUBJECT$ (CMF [cyclophosphamide, methotrexate, 5-fluorouracil] schedule) or hormone therapy (tamoxifen). |
Fact | preserve | 136-143 | 136-143 | T12 | treated | TREATS | 136 | 143 | preserve | 162-183 | 171-183 | T7 | adjuvant chemotherapy | TherapeuticOrPreventiveProcedure | 162 | 183 | preserve | 122-135 | 129-135 | T6 | breast cancer | NeoplasticProcess | 122 | 135 | A11 | Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. | 0-203 | 0 | 203 | Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive @OBJECT$ @PREDICAT$ with either @SUBJECT$ or hormone therapy. |
Fact | preserve | 3825-3829 | 3825-3829 | T255 | with | PROCESS_OF | 3,825 | 3,829 | preserve | 3830-3834 | 3830-3834 | T246 | NPBC | NeoplasticProcess | 3,830 | 3,834 | preserve | 3816-3824 | 3816-3824 | T244 | patients | PatientOrDisabledGroup | 3,816 | 3,824 | A14 | This information may be useful to plan future studies to better select the patients with NPBC for conventional adjuvant treatments as well as to monitor the efficacy of novel therapeutic strategies of adjuvant therapy based on inhibition of angiogenesis. | 3735-4009 | 3,735 | 4,009 | This information may be useful to plan future studies to better select the @OBJECT$ @PREDICAT$ @SUBJECT$ for conventional adjuvant treatments as well as to monitor the efficacy of novel therapeutic strategies of adjuvant therapy based on inhibition of angiogenesis. |